Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Self-reported adherence versus pill count in Parkinson's disease: the NET-PD experience.

Elm JJ, Kamp C, Tilley BC, Guimaraes P, Fraser D, Deppen P, Brocht A, Weaver C, Bennett S; NINDS NET-PD Investigators and Coordinators.

Mov Disord. 2007 Apr 30;22(6):822-7.

PMID:
17357141
2.

Adherence to anti-Parkinson drug therapy in the "REASON" sample of Italian patients with Parkinson's disease: the linguistic validation of the Italian version of the "Morisky Medical Adherence Scale-8 items".

Fabbrini G, Abbruzzese G, Barone P, Antonini A, Tinazzi M, Castegnaro G, Rizzoli S, Morisky DE, Lessi P, Ceravolo R; REASON study group.

Neurol Sci. 2013 Nov;34(11):2015-22. doi: 10.1007/s10072-013-1438-1. Epub 2013 Jun 1.

PMID:
23728715
3.

The use of carer assisted adherence therapy for people with Parkinson's disease and their carers (CAAT-PARK): study protocol for a randomised controlled trial.

Daley DJ, Deane KH, Gray RJ, Worth PF, Clark AB, Sabanathan K, Pfeil M, Myint PK.

Trials. 2011 Nov 28;12:251. doi: 10.1186/1745-6215-12-251.

4.

Measuring therapy adherence in Parkinson's disease: a comparison of methods.

Grosset KA, Bone I, Reid JL, Grosset D.

J Neurol Neurosurg Psychiatry. 2006 Feb;77(2):249-51.

5.

Drug adherence in Parkinson's disease.

Leopold NA, Polansky M, Hurka MR.

Mov Disord. 2004 May;19(5):513-7.

PMID:
15133814
6.

Antiparkinson drug use and adherence in medicare part D beneficiaries with Parkinson's disease.

Wei YJ, Palumbo FB, Simoni-Wastila L, Shulman LM, Stuart B, Beardsley R, Brown C.

Clin Ther. 2013 Oct;35(10):1513-1525.e1. doi: 10.1016/j.clinthera.2013.09.001.

PMID:
24139423
7.

Prevalence and cost of medication nonadherence in Parkinson's disease: evidence from administrative claims data.

Davis KL, Edin HM, Allen JK.

Mov Disord. 2010 Mar 15;25(4):474-80. doi: 10.1002/mds.22999.

PMID:
20131374
8.

Validation of patient reports, automated pharmacy records, and pill counts with electronic monitoring of adherence to antihypertensive therapy.

Choo PW, Rand CS, Inui TS, Lee ML, Cain E, Cordeiro-Breault M, Canning C, Platt R.

Med Care. 1999 Sep;37(9):846-57.

PMID:
10493464
9.

[Insufficient medication compliance in Parkinson's disease].

Aerts MB, van der Eijk M, Kramers K, Bloem BR.

Ned Tijdschr Geneeskd. 2011;155:A3031. Review. Dutch.

PMID:
21527053
10.

Suboptimal medication adherence in Parkinson's disease.

Grosset KA, Bone I, Grosset DG.

Mov Disord. 2005 Nov;20(11):1502-7.

PMID:
16037924
11.

Systematic review on factors associated with medication non-adherence in Parkinson's disease.

Daley DJ, Myint PK, Gray RJ, Deane KH.

Parkinsonism Relat Disord. 2012 Dec;18(10):1053-61. doi: 10.1016/j.parkreldis.2012.09.004. Epub 2012 Sep 28. Review.

PMID:
23022461
12.

Socio-demographic and clinical factors influencing the adherence to treatment in Parkinson's disease: the ADHESON study.

Valldeoriola F, Coronell C, Pont C, Buongiorno MT, Cámara A, Gaig C, Compta Y; ADHESON Study Group.

Eur J Neurol. 2011 Jul;18(7):980-7. doi: 10.1111/j.1468-1331.2010.03320.x. Epub 2010 Dec 29.

PMID:
21199185
13.

Medication adherence and associated outcomes in medicare health maintenance organization-enrolled older adults with Parkinson's disease.

Kulkarni AS, Balkrishnan R, Anderson RT, Edin HM, Kirsch J, Stacy MA.

Mov Disord. 2008 Feb 15;23(3):359-65.

PMID:
18074366
14.

Development of a new scale to measure self-reported medication nonadherence.

Unni EJ, Farris KB.

Res Social Adm Pharm. 2015 May-Jun;11(3):e133-43. doi: 10.1016/j.sapharm.2009.06.005. Epub 2009 Oct 9.

PMID:
21272524
15.

A multicenter, open-label, sequential study comparing preferences for carbidopa-levodopa orally disintegrating tablets and conventional tablets in subjects with Parkinson's disease.

Nausieda PA, Pfeiffer RF, Tagliati M, Kastenholz KV, DeRoche C, Slevin JT.

Clin Ther. 2005 Jan;27(1):58-63. Erratum in: Clin Ther. 2005 Mar;27(3):360.

PMID:
15763606
16.
17.

Assessment of adherence to antiretroviral therapy in perinatally HIV-infected children and youth using self-report measures and pill count.

Farley JJ, Montepiedra G, Storm D, Sirois PA, Malee K, Garvie P, Kammerer B, Naar-King S, Nichols S; PACTG P1042S Team.

J Dev Behav Pediatr. 2008 Oct;29(5):377-84. doi: 10.1097/DBP.0b013e3181856d22.

PMID:
18714204
18.

Antiparkinson drug adherence and its association with health care utilization and economic outcomes in a Medicare Part D population.

Wei YJ, Palumbo FB, Simoni-Wastila L, Shulman LM, Stuart B, Beardsley R, Brown CH.

Value Health. 2014 Mar;17(2):196-204. doi: 10.1016/j.jval.2013.12.003.

19.

Do Parkinson's disease patients disclose their adverse events spontaneously?

Perez-Lloret S, Rey MV, Fabre N, Ory F, Spampinato U, Montastruc JL, Rascol O.

Eur J Clin Pharmacol. 2012 May;68(5):857-65. doi: 10.1007/s00228-011-1198-x. Epub 2011 Dec 29.

PMID:
22205275
20.

Medication nonadherence in older people with serious mental illness: prevalence and correlates.

Pratt SI, Mueser KT, Driscoll M, Wolfe R, Bartels SJ.

Psychiatr Rehabil J. 2006 Spring;29(4):299-310.

PMID:
16689041

Supplemental Content

Support Center